Your browser doesn't support javascript.
loading
Treatment of Chronic Heart Failure Patients with Qi-Yang Deficiency and Blood Stasis Resistance Syndrome by Xnmallong Injection: a Multi-center Randomized Control Study / 中国中西医结合杂志
Chinese Journal of Integrated Traditional and Western Medicine ; (12): 796-800, 2015.
Article Dans Chinois | WPRIM | ID: wpr-237936
ABSTRACT
<p><b>OBJECTIVE</b>To evaluate the efficacy and safety of Xinmailong Injection (XI) in treatment of chronic heart failure (CHF) patients with qi-yang deficiency and blood stasis resistance syndrome (QY-DBSRS).</p><p><b>METHODS</b>Totally 238 CHF patients with QYDBSRS were assigned to the treatment group (118 cases) and the control group (120 cases) by randomized, double-blind, placebo parallel controlled method. Patients in the treatment group received routine therapy and XI (100 mg/2 mL, by dripping at 5 mg/kg, twice per day for 5 consecutive days), while those in the control group received routine therapy and XI mimetic agent (100 mg/2 mL, by dripping at 5 mg/kg, twice per day for 5 consecutive days). The heart function classification of New York Heart Association (NYHA), 6-min walking distance, left ventricular ejection fraction (LVEF), scores for Chinese medical symptoms were observed before and after treatment, and safety assessed.</p><p><b>RESULTS</b>Totally 235 patients actually entered full analysis set (FAS), including 120 cases in the control group and 115 cases in the treatment group. The total effective rate of heart function, 6-min walking distance and increased post-pre-treatment distance in the experimental group were superior to those of the control group with statistical difference (all P < 0.05). Compared with the control group, increased value of post-pre-treatment LVEF, the total effective rate of Chinese medical syndrome efficacy, scores for Chinese medical symptoms and decreased post-pre-treatment value of Chinese medical syndrome scores were obviously improved (all P < 0.05). There was no significant difference in the incidence of adverse events between the two groups (P > 0.05).</p><p><b>CONCLUSIONS</b>XI could improve the heart function of CHF patients, improve Chinese medical symptoms, elevate exercise tolerance, and improve LVEF. It had no obvious toxic and side effects.</p>
Sujets)
Texte intégral: Disponible Indice: WPRIM (Pacifique occidental) Sujet Principal: Pharmacologie / Syndrome / Médicaments issus de plantes chinoises / Méthode en double aveugle / Maladie chronique / Déficit du Yang / Qi / Utilisations thérapeutiques / Traitement médicamenteux / Défaillance cardiaque Type d'étude: Essai clinique contrôlé / Etude diagnostique Limites du sujet: Humains langue: Chinois Texte intégral: Chinese Journal of Integrated Traditional and Western Medicine Année: 2015 Type: Article

Documents relatifs à ce sujet

MEDLINE

...
LILACS

LIS

Texte intégral: Disponible Indice: WPRIM (Pacifique occidental) Sujet Principal: Pharmacologie / Syndrome / Médicaments issus de plantes chinoises / Méthode en double aveugle / Maladie chronique / Déficit du Yang / Qi / Utilisations thérapeutiques / Traitement médicamenteux / Défaillance cardiaque Type d'étude: Essai clinique contrôlé / Etude diagnostique Limites du sujet: Humains langue: Chinois Texte intégral: Chinese Journal of Integrated Traditional and Western Medicine Année: 2015 Type: Article